Ianalumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ianalumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ianalumab can convert its Monoclonal antibody profile and BAFF-R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ianalumab (query alias: Ianalumab) |
|---|---|
| Modality / target | Monoclonal antibody; BAFF-R; BAFF-R inhibitors |
| Highest global status | NDA/BLA |
| Originator | MorphoSys AG |
| Active developers | Novartis Pharma AG, Lonza AG, Novartis Pharmaceuticals Corp. |
The MCP disease footprint includes Immune System Diseases, Sjogren's Syndrome, Systemic Lupus Erythematosus. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07621809 | Phase 3 | Recruiting | 570 | Change from baseline in SSSD oral dryness score |
| NCT07421167 | Phase 2 | Recruiting | 164 | (Main cohort: Primary immune thrombocytopenia (ITP)): Percentages of participants who are tolerable to ianalumab (9 mg/kg) |
| NCT07660172 | Phase 2 | Not yet recruiting | 36 | Time to treatment failure (TTF) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
EVALUATION OF THE IANALUMAB TREATMENT EFFECTS ON PAROTID AND SUBMANDIBULAR GLANDS OF PATIENTS WITH SJÖGREN’S DISEASE BY MULTIMODAL ULTRASOUND: RESULTS FROM A PHASE 2 MECHANISTIC STUDY
Phase 2; n=21; evaluation: Positive. Reported fields: OMERACT disease staging score = The proportion of participants with an OMERACT disease staging score of 0 or 1 for their worst PGs or SMGs increased on treatment from 12% to 24% and 30% for PGs, and from 18% to 29% and 41% for SMGs at BL, Week 13 and Week 25, respectively.
SAFETY AND EFFICACY OF SUBCUTANEOUS IANALUMAB (VAY736) POST-B CELL RECOVERY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: END OF STUDY RESULTS FROM A PHASE 2 STUDY
Phase 2; n=67; evaluation: Positive. Reported fields: SRI-4(Week 28) = 30.3 % ; SRI-4(Week 28) = 70.6 %
EFFECT OF IANALUMAB PLUS ELTROMBOPAG ON PATIENT-REPORTED OUTCOMES IN PRIMARY IMMUNE THROMBOCYTOPENIA: RESULTS FROM THE VAYHIT2 PHASE 3 TRIAL
Phase 3; n=152; evaluation: Positive. Reported fields: ITP-PAQ Activity(25-week) = 22.8 point ; ITP-PAQ Activity(25-week) = 25.0 point ; ITP-PAQ Activity(25-week) = 20.5 point
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ianalumab addresses Immune System Diseases, Sjogren's Syndrome, Systemic Lupus Erythematosus. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2007-12-02 | MorphoSys and Novartis Forge New Strategic Alliance to Establish Innovative Therapeutic Antibody Pipeline | Discovery | US$600.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
